Asset profile
HRS-4508
Small molecule
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
73 competitors in this universe: 12 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 68 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| HRS-4508: this drug | Phase 2 | Small molecule | HER2 | ||
| Trastuzumab Deruxtecan | Approved | Antibody–drug conjugate | HER2 | ||
| Zanidatamab | Approved | Multispecific antibody | HER2 | ||
| Zongertinib | Approved | Small molecule | HER2, HER2 Mutant-selective | ||
| BL-M07D1 | Phase 3 | Antibody–drug conjugate | HER2 | ||
| Disitamab Vedotin | Phase 3 | Antibody–drug conjugate | HER2 | ||
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | ||
| Tucatinib | Phase 3 | Small molecule | HER2 | ||
| 177Lu-DWJ155 | Phase 1 | Radiopharmaceutical | HER2 | ||
| BL-M17D1 | Phase 1 | Antibody–drug conjugate | HER2 | ||
| KJ015 | Phase 1 | Monoclonal antibody | HER2 | ||
| MT-304 | Phase 1 | Cell therapy | HER2 | ||
| NVL-330 | Phase 1 | Small molecule | HER2 | ||
| DB-1303 | Phase 3 | Monoclonal antibody | HER2 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK |
…and 58 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (5)
September 2027 (1)
October 2027 (1)
December 2027 (3)
What to watch
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.